Observational studies[10, 11, 26] found no increase in aggressive or any prostate cancer in testosterone-treated men but their conclusions were limited by the absence of an appropriate comparison group, lack of adjustment for PSA screening and lack of cumulative dosage analyses. Here, KLK3 is linked to prostate cancer.